Navigation Links
MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
Date:12/15/2008

Live Broadcast on December 18, 2008 at 9 a.m. Eastern Time

VALENCIA, Calif., Dec. 15 /PRNewswire-FirstCall/ --MannKind Corporation (Nasdaq: MNKD) will host a live broadcast to review clinical results from its final two Phase 3 studies of AFRESA(TM), the company's ultra rapid acting, inhaled insulin product, at 9 a.m. Eastern Time on Thursday, December 18, 2008.

To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in viewing the live webcast via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com.

A telephone replay of the call will be accessible for approximately fourteen days following completion of the call by dialing (800) 873-5860 or (203) 369-3996. A replay will also be available on MannKind's website for fourteen days.

About AFRESA

Afresa is an ultra rapid acting inhaled insulin product that has completed Phase 3 trials. The pharmacokinetic profile of Afresa sets it apart from all other insulin products. The large surface area of the lung provides unique access to the circulatory system. The pH-sensitive Afresa particles immediately dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstream. It achieves peak insulin levels within 12-14 minutes of administration, effectively mimicking the release of meal-time insulin observed in healthy individuals, but which is absent from patients with diabetes.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercializatio
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
2. MannKind Addresses Pfizers Announcement Regarding Exubera
3. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
4. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
6. Successful Results for Mymetics Corporations Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations
7. National Jewish Health and Roche Diagnostics Corporation Reach Agreement to Pursue Environmental Molecular Diagnostics Opportunities
8. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
9. Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
10. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
11. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015 CytRx Corporation ... development company specializing in oncology, today announced that ... Executive Officer, and David Haen , Vice ... present a corporate overview at two significant investment ... and healthcare industries: the FBR & Co. Second ...
(Date:9/1/2015)... 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ... development and sale of broadly enabling, pressure cycling ... life sciences industry, today announced the publication of ... PCT Platform could play a significant role in ... is based on PCT,s unique ability to help ...
(Date:9/1/2015)... BerGenBio AS ("BerGenBio" or the ... has appointed Hilde Furberg and Dr ... of Directors, effective immediately. Hilde Furberg ... and biotech and is currently Senior Vice President Rare ... role was Vice President and General Manager of Nordic ...
Breaking Medicine Technology:CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 2CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 3CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 3New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 5BerGenBio Appoints Non-Executive Directors 2
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... Cleveland Clinic, ranked a top-five hospital by U.S. News & World Report, to ... cancer patients. , Editorial and marketing groups within OncLive, which provides oncologists ...
(Date:9/1/2015)... PA (PRWEB) , ... September 01, 2015 , ... The ... 18 at The ACE Club and Green Valley Country Club in Lafayette Hill, PA. ... has raised more than $13.5 million for programs and services designed to support patients ...
(Date:9/1/2015)... ... 01, 2015 , ... With former IBMers among its founding members, Inmar has ... more than 35 years ago. A pilot program begun by the company in 2014 ... just those intent on pursuing careers in these fields. The program is now open ...
(Date:9/1/2015)... ... September 01, 2015 , ... e-Spirit Inc., a leading ... the FirstSpirit Content Management System with new capabilities and enhancements designed to support ... companies will be well on their way to achieving digital transformation with less ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Zecurion, a ... Mac , its groundbreaking new version of endpoint DLP developed specifically for Mac OS. ... in which more than 100 IT and information security professionals had participated. The beta ...
Breaking Medicine News(10 mins):Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Zecurion Announces Endpoint Security for Mac 2
... suffer a break up to eight times more likely to die, ... and women who break a hip are five to eight times ... fracture, a new study by Belgian researchers has found. , And, ... the first two years after the break, it never returns to ...
... , MONDAY, March 15 (HealthDay News) -- A ... sexual dysfunction in people with Parkinson,s disease has been ... main symptoms of Parkinson,s disease are movement problems, but ... noted lead guidelines author Dr. Theresa A. Zesiewicz, of ...
... boomer epidemic predicted , MONDAY, March 15 (HealthDay News) -- ... the 1990s, making it by far the most common form ... two new studies find. , More than 2 million Americans ... up from 1.6 million in 1992, according to one study. ...
... ... identify infants at high risk of developing childhood-onset obesity by measuring a newborn baby’s ... possible is called the Pea Pod® Infant Body Composition System. Located at Prentice Women’s ... , ...
... (TSE: 4503) today released the following statement in response to OSI Pharmaceuticals, (Nasdaq: OSIP ) rejection of Astellas, tender offer for $52.00 per share. , ... , ... ... ...
... are focused on the issue 24/7. , ... , , ... ... Rotary is committed to helping achieve the UN Millennium Development Goal that calls for a 50 percent reduction ...
Cached Medicine News:Health News:Risk of Death Persists After a Hip Fracture 2Health News:Risk of Death Persists After a Hip Fracture 3Health News:Relief Sought for Secondary Parkinson's Symptoms 2Health News:Non-Melanoma Skin Cancers in the Millions and Rising 2Health News:Non-Melanoma Skin Cancers in the Millions and Rising 3Health News:Non-Melanoma Skin Cancers in the Millions and Rising 4Health News:Study to Identify Infants at High Risk for Developing Obesity 2Health News:Study to Identify Infants at High Risk for Developing Obesity 3Health News:Astellas Responds to OSI Pharmaceuticals' Rejection 2Health News:Astellas Responds to OSI Pharmaceuticals' Rejection 3Health News:Astellas Responds to OSI Pharmaceuticals' Rejection 4Health News:Astellas Responds to OSI Pharmaceuticals' Rejection 5Health News:Astellas Responds to OSI Pharmaceuticals' Rejection 6Health News:Astellas Responds to OSI Pharmaceuticals' Rejection 7Health News:Rotary Clubs Always Pumped for World Water Day 2Health News:Rotary Clubs Always Pumped for World Water Day 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: